SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): May 22, 2002
Date of Filing: May 23, 2002
|
|
RIGEL PHARMACEUTICALS, INC. |
|
|
|
(Exact name of registrant as specified in its charter) |
|
|
Delaware |
|
0-29889 |
|
94-3248524 |
|
(State of jurisdiction) |
|
(Commission File No.) |
|
(IRS Employer Identification No.) |
|
|
240 East Grand Avenue, South San Francisco, CA 94080 |
|
|
|
(Address of principal executive offices and zip code) |
|
|
|
|
|
|
|
(650) 624-1100 |
|
|
|
Registrant’s telephone number, including area code: |
|
Item 5. Other Events
On May 22, 2002, Rigel Pharmaceuticals, Inc. issued a press release entitled “Rigel Announces Novartis’ Acceptance of Drug Target and Conclusion of Research Phase of Two Programs.” A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
|
Number |
|
Description |
|
|
|
|
|
99.1 |
|
Press release entitled “Rigel Announces Novartis’ Acceptance of Drug Target and Conclusion of Research Phase of Two Programs,” dated May 22, 2002. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
RIGEL PHARMACEUTICALS, INC. |
|
|
|
|
|
|
Dated: May 23, 2002 |
By: |
/s/ James H. Welch |
|
|
|
James H. Welch Vice President, Chief Financial Officer and Secretary |
|
|
|
|
EXHIBIT INDEX
|
Number |
|
Description |
|
|
|
|
|
99.1 |
|
Press release entitled “Rigel Announces Novartis’ Acceptance of Drug Target and Conclusion of Research Phase of Two Programs,” dated May 22, 2002. |